Easton Capital Investment Group manages approximately $200 million on behalf of a number of significant institutional investors in its funds, including: Easton Hunt Capital Partners, L.P., Easton Capital Partners, L.P. Easton Hunt New York L.P, Easton New Media Fund, LP  Easton Special Situations Fund I, LLC (ESSF I) and Easton Special Situations Fund II, LLC (ESSF II). Easton has made investments ranging in size from $500,000 to $7.5 million and has strategic co-investment relationships with many of its institutional investors which allow it to participate in larger initial and follow-on rounds of funding.

About Easton: Positioned For Success

Easton has a long history of investing in healthcare though it has historically also invested in certain other sectors.  Given the current state of the market, Easton is now focusing solely on the healthcare sector because of the unique risk – reward ratio it presents.

The healthcare industry is one of the foundations of the US. economy, providing an engine for innovation and new job creation. The US has a unique place in creating new enterprises and technology in healthcare and the life sciences.  Easton believes that the US will maintain its lead as a driver of innovation and progress in the delivery of healthcare and that the venture capital community will remain a vital link in the introduction of new healthcare services and products.  Our role at Easton is to identify, nurture and support the commercial introduction of those technologies, products and companies that will shape the emerging landscape.
 
We are entering a rich stage of development in the life sciences sector. Leveraging the significant increases in the knowledge of biology from the past decade, there is a unique opportunity to create new products in a capital efficient manner, since a self-supporting strong business model is as important as the underlying science. Coupled with an aging population that seeks innovation to enhance its increased life expectancy, the healthcare and life sciences sectors have become even more attractive, as a defensive strategy with virtually unlimited upside.  We see significant growth not only in the developed world, but also in the emerging markets as more people are able to both access and afford better healthcare.  

As pharmaceutical companies struggle to fill their pipelines decimated by the on-going patent cliff, there’s an unparalleled opportunity to exit healthcare businesses through strategic acquisition, thus decoupling liquidity events from the public markets

At Easton, we bring you more than 100 years of Life Science investing experience through a team of seasoned industry veterans who will help you be a part of these exciting possibilities in investment.